/NAGE
NAGE Stock - Niagen Bioscience Inc
Healthcare|BiotechnologyNASDAQ
$6.52+0.31%
+$0.02 (+0.31%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.28
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+114.7%upside
Target: $14.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NAGE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.45 – $6.59
TARGET (TP)$14.00
STOP LOSS$6.00
RISK/REWARD1:14.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.31
52W High$14.69
52W Low$5.16
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $99.60M | $83.57M | $72.05M | $67.45M | $59.26M |
| Gross Profit | $61.59M | $50.78M | $42.80M | $41.49M | $35.27M |
| Gross Margin | 61.8% | 60.8% | 59.4% | 61.5% | 59.5% |
| Operating Income | $7.73M | $-5,599,000 | $-18,628,000 | $-27,073,000 | $-19,854,000 |
| Net Income | $8.55M | $-4,938,000 | $-16,540,000 | $-27,128,000 | $-19,925,000 |
| Net Margin | 8.6% | -5.9% | -23.0% | -40.2% | -33.6% |
| EPS | $0.10 | $-0.07 | $-0.24 | $-0.40 | $-0.33 |
Company Overview
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 99.4% Upside
Now
$13
Low
$13
Average
$13
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 27th 2025 | Canaccord Genuity | Initiation | Buy | $13 |
Earnings History & Surprises
NAGEBeat Rate
100%
Last 11 quarters
Avg Surprise
+90.9%
EPS vs Estimate
Beats / Misses
11/0
Last 12 quarters
Latest EPS
$0.05
Q4 2025
EPS Surprise History
Q4 23
+106.8%
$0.00vs$-0.02
Q1 24
+67.3%
$-0.01vs$-0.02
Q2 24
+99.0%
$-0.00vs$-0.02
Q4 24
+100.0%
$0.02vs$0.01
Q1 25
+50.0%
$0.03vs$0.02
Q2 25
+100.0%
$0.04vs$0.02
Q3 25
+100.0%
$0.04vs$0.02
Q4 25
+233.3%
$0.05vs$0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.01 | $0.05 | +233.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $0.02 | $0.03 | +50.0% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $0.01 | $0.02 | +100.0% | ✓ BEAT |
Q2 2024 | Jun 30, 2024 | $-0.02 | $-0.00 | +99.0% | ✓ BEAT |
Q1 2024 | Mar 31, 2024 | $-0.02 | $-0.01 | +67.3% | ✓ BEAT |
Q4 2023 | Dec 31, 2023 | $-0.02 | $0.00 | +106.8% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $-0.03 | $-0.01 | +57.4% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.04 | $-0.03 | +26.9% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | — | $-0.03 | — | — |
Q4 2022 | Dec 31, 2022 | $-0.05 | $-0.02 | +58.8% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.09 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.11 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.08 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.13 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.08 | — | — |
Latest News
Niagen Bioscience Launches Tru Niagen Beauty Supplement In U.S.
📈 PositiveBenzinga•Nov 13, 2025, 01:44 PM
Reported Earlier, Niagen Bioscience Announces Clinical Trial Results Showing Ten Weeks Of Niagen NR Supplementation Increased NAD+ Levels And Improved Fatigue Sleep Quality And Depression In Long COVID
📈 PositiveBenzinga•Nov 13, 2025, 07:16 AM
Niagen Bioscience Announces $10M Share Repurchase Program
📈 PositiveBenzinga•Nov 6, 2025, 01:12 PM
Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $14
📈 PositiveBenzinga•Nov 5, 2025, 06:20 PM•Also:
Niagen Bioscience shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 4, 2025, 09:59 PM
Niagen Bioscience Affirms FY2025 Sales Guidance of $124.496M-$129.476M vs $126.462M Est
➖ NeutralBenzinga•Nov 4, 2025, 09:03 PM
Niagen Bioscience Q3 EPS $0.05 Beats $0.02 Estimate, Sales $33.986M Beat $31.102M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:02 PM
Niagen Bioscience Announces It Has Increased Its FY25 Net Sales Outlook To 25% To 30% YoY Growth From 22% To 27%
📈 PositiveBenzinga•Oct 6, 2025, 12:39 PM
Frequently Asked Questions about NAGE
What is NAGE's current stock price?
Niagen Bioscience Inc (NAGE) is currently trading at $6.52 per share. The stock has moved +0.31% today.
What is the analyst price target for NAGE?
The average analyst price target for NAGE is $14.00, based on 1 analyst.
What sector is Niagen Bioscience Inc in?
Niagen Bioscience Inc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NAGE's market cap?
Niagen Bioscience Inc has a market capitalization of $0.52 billion, making it a small-cap company.
Does NAGE pay dividends?
No, Niagen Bioscience Inc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKBA
Akebia Therapeutics, Inc.
$1.66
Mkt Cap: $0.4B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
KROS
Keros Therapeutics, Inc.
$20.26
Mkt Cap: $0.8B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
ZVRA
Zevra Therapeutics, Inc.
$8.31
Mkt Cap: $0.5B
Explore stocks similar to NAGE for comparison